2Q26 Strongly Beat Expectations; Full-Year Revenue Growth Guidance Raised to 35%—39%

Overview

The report reviews WuXi AppTec Co Ltd's 2Q26 and 1H26 results. The company delivered strong revenue, net profit, and adjusted net profit, and significantly raised its full-year continuing operations revenue growth guidance. Morgan Stanley believes the main drivers of the beat were increases in commercial contracts, backlog expansion, TIDES business acceleration, strong revenue growth from U.S. customers, and improved capacity utilization; therefore, it reiterates A-shares as its top pick and maintains an Overweight rating.

Core views

The quality of growth is reflected not only in the current-period earnings beat but also supported by orders and project mix. Six new commercial contracts were added in 2Q, bringing the year-to-date additions to 12 and the total to 95, with most still under market exclusivity or patent protection; backlog orders increased 25% YoY to Rmb66.4bn. TIDES revenue accelerated from 6% YoY growth in 1Q to 75% growth in 2Q, and full-year growth guidance was raised from 40% to 45%. 1H26 U.S. revenue grew 62% YoY and accounted for 77% of total revenue, indicating that U.S. demand remains strong. As projects advance to later stages and capacity utilization improves, the adjusted gross margin of the chemistry business rose to 56.4%.

Analysis framework

The report uses comparisons between results and institutional forecasts, segment revenue growth analysis, tracking of commercial contracts and backlog orders, regional revenue mix analysis, margin and capital expenditure assessment, and derives the A-share target price through discounted cash flow valuation; the H-share target price is derived from the A-share target price combined with an exchange rate assumption.

Methodology notes

• Valuation methodDiscounted Cash Flow Method

  Determines the A-share base-case value by discounting future free cash flows.

  The base case uses a weighted average cost of capital of 10% and a perpetual growth rate of 4%.

• Operating metricsBook-to-Bill Tracking

  Assesses CDMO business momentum quarterly by combining revenue, backlog orders, and the number of commercialized and Phase III projects.

  The report notes that the relevant ratio remained above 1.20 from 1Q25 to 2Q26, and views the number of commercial contracts as an important driver of manufacturing CDMO backlog and revenue.

• Earnings forecastMorgan Stanley ModelWare

  An internal modeling framework used to form forecasts for revenue, profit, earnings per share, and valuation multiples.

  Unless otherwise stated, the forecast metrics in the report are based on the Morgan Stanley ModelWare framework.

• Cross-market valuationA-share to H-share Target Price Conversion

  Derives the H-share target price based on the A-share target price and exchange rate assumptions.

  The report uses an exchange rate assumption of HKD:RMB at 1.10.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• WuXi AppTec Co Ltd（603259.SS）

  The main covered company in the report and Morgan Stanley's top pick in China's healthcare sector.

  Strengths

  Results significantly beat expectations, full-year guidance raised, growth in commercial contracts and backlog orders, TIDES acceleration, and improvements in capacity utilization and gross margin.

  Weaknesses

  High share of U.S. revenue, and higher capex may increase execution and investment return pressure.

  Comparison

  A-shares are valued using the discounted cash flow method, with a target price of Rmb153.00, implying 19% potential upside versus the current price of Rmb128.50.

  Risks

  End sales of drugs corresponding to commercialized projects falling short of expectations, patent expirations, financing environment volatility, and changes in U.S.-China relations.

• WuXi AppTec Co Ltd（2359.HK）

  The same company's H-share listed security, with the target price derived by converting the A-share valuation.

  Strengths

  Shares the company's logic of order growth, business acceleration, and margin improvement.

  Weaknesses

  In addition to fundamental risks, it is also affected by A/H-share valuation differences and exchange rate movements.

  Comparison

  The H-share target price is based on the A-share target price and uses an exchange rate assumption of HKD:RMB at 1.10.

  Risks

  Deviation from exchange rate assumptions, changes in cross-market valuation premiums/discounts, and company-level geopolitical and operational risks.

Key data

• Full-year continuing operations revenue growth guidance35%—39%Previously 18%—22%, corresponding to revenue of Rmb58.5—60.5bn.
• 1H26 continuing operations revenueRmb28.9bnUp 38.9% YoY and 15% above Morgan Stanley's forecast.
• 1H26 net profitRmb11.1bnUp 29.4% YoY and 12% above Morgan Stanley's forecast.
• 2Q26 revenueRmb16.5bnUp 47.7% YoY and 29% above Morgan Stanley's forecast.
• 2Q26 net profitRmb6,429mnUp 35.3% YoY and 23% above Morgan Stanley's forecast.
• Adjusted net profit growth1H26 growth of 83.2%; 2Q26 growth of 91.7%Mainly excludes the impact of partial sale of WuXi XDC equity and the sale of the CRO business.
• 2Q26 segment revenue growthSmall Molecule Research +11%; Small Molecule Development and Manufacturing +67%; TIDES +75%; Testing +35%; Biology +12%All are year-on-year growth rates.
• Backlog ordersRmb66.4bnUp 25% YoY and 11% QoQ.
• Number of commercial contracts95Six added in 2Q, with 12 added year to date.
• 1H26 U.S. revenueUp 62% YoYAccounted for 77% of the company's total revenue, higher than 71% in 1H25.
• Adjusted gross margin of the chemistry business56.4%Up 7.4 percentage points YoY, mainly benefiting from higher capacity utilization and projects advancing to later stages.
• Full-year capex guidanceRmb7.5—8.5bnPreviously Rmb6.5—7.5bn; full-year adjusted net margin is expected to remain stable.
• A-share valuation snapshotTarget price Rmb153.00, current price Rmb128.50Corresponds to 19% potential upside, with an Overweight rating.

Impact & implications

The significantly raised revenue guidance may drive upward revisions to market consensus EPS over the next 12 months. Expansion in commercial contracts and backlog orders improves medium-term revenue visibility, while TIDES and new technology platforms provide structural incremental growth. The continued rise in the share of U.S. revenue may alleviate some geopolitical concerns in the short term, but also means the company remains highly sensitive to the U.S. market and U.S.-China relations. The capex increase indicates the company is expanding capacity to meet demand growth, with returns depending on order conversion, capacity ramp-up, and margin stability.

Risks

• End sales of drugs corresponding to important commercial contracts are lower than expected, or orders are affected by the end of patent and market exclusivity periods.
• Volatility in VC/PE financing in the biopharmaceutical industry may weaken demand for early-stage R&D and outsourcing services.
• Changes in U.S.-China relations and related regulatory policies may affect customer cooperation, order acquisition, and valuation.
• After the increase in capex, if order conversion or capacity ramp-up falls short of expectations, investment returns may be compressed.
• U.S. revenue accounts for 77%, and the high market concentration increases exposure to regional demand and policy risks.
• Morgan Stanley disclosed that it has shareholding and investment banking relationships with WuXi AppTec Co Ltd, and investors should pay attention to potential conflicts of interest.

What to watch

• Whether full-year continuing operations revenue can reach the guidance range of Rmb58.5—60.5bn.
• The number of new commercial contracts and the pace of revenue conversion from the Rmb66.4bn backlog.
• Whether TIDES can achieve full-year revenue growth guidance of about 45%.
• Whether the book-to-bill ratio can continue to remain above 1.20.
• Whether the chemistry business gross margin can remain at a high level as capacity utilization improves.
• Deployment progress of Rmb7.5—8.5bn capex and utilization of newly added capacity.
• U.S. revenue growth, customer stability, and changes in the U.S.-China policy environment.
• Whether full-year adjusted net margin can remain stable, and the magnitude of upward revisions to market consensus EPS.